Seminars in Oncology
Volume 33 , Pages S26-S34 , October 2006

Bevacizumab in the Treatment of Metastatic Colorectal Cancer: Safety Profile and Management of Adverse Events

  • Herbert Hurwitz

      Affiliations

    • Dr Hurwitz has received research support from Genentech, Roche, Pfizer, AstraZeneca, GlaxoSmithKline, Sunesis, Bristol-Myers Squibb, and Sanofi-Aventis. Dr Saini has received research support from GlaxoSmithKline.
    • Corresponding Author InformationAddress reprint requests to Herbert Hurwitz, MD, Box 3052, Room 3802 Red Zone, Duke South Clinics, Duke University Medical Center, Durham, NC 27710, USA.
    • ,
  • Shermini Saini

References 

  1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  2. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706–3712
  3. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. J Clin Oncol. 2006;24(suppl):148s;(abstr 3510)
  4. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol. 2005;23(suppl):1s;(abstr 2)
  5. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol. 2005;23:3697–3705
  6. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502–3508
  7. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65
  8. Avastin (bevacizumab) prescribing information. South San Francisco, CA: Genentech; 2006;
  9. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005;69(suppl 3):25–33
  10. Novotny W, Holmgren E, Nelson B, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer. J Clin Oncol. 2004;22:252;(abstr 3529)
  11. Sutent (sunitinib malate) prescribing information. New York, NY: Pfizer; 2006;
  12. Nexavar (sorafenib) prescribing information. Emeryville, CA: Onyx Pharmaceuticals; 2005;
  13. Dupont J, Schwartz L, Koutcher J, et al. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously to patients with advanced solid malignancies. J Clin Oncol. 2004;22:197;(abstr 3009)
  14. Rosen L, Kurzrock R, Jackson E, et al. Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors. J Clin Oncol. 2005;23(suppl):195s;(abstr 3013)
  15. Morris C, Jurgensmeier J, Robertson J, et al. AZD2171, an oral, highly potent, and reversible inhibitor of VEGFR, signaling with potential for the treatment of advanced colorectal cancer. 2006;Presented at 2006 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, San Francisco, CA, January 28–30, (abstr 242)
  16. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–799
  17. Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat. 2005;94(suppl 1):S6;(abstr 3)
  18. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non–small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol. 2005;23(suppl):2s;(abstr LBA4)
  19. National Heart Lung and Blood Institute. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) NIH Publication No. 04-5230, 2004. Available at: http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbpdiab.txt (accessed July 19, 2006)
  20. Ma L, Francia G, Viloria-Petit A, et al. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: Modulation by lower-dose chemotherapy. Cancer Res. 2005;65:5365–5373
  21. Skillings JR, Johnson DH, Miller K, et al. Arterial thromboembolic events in a pooled analysis of 5 randomized, controlled trials of bevacizumab with chemotherapy. J Clin Oncol. 2005;23(suppl):196s;(abstr 3019)
  22. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non–small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191
  23. Hambleton J, Skillings J, Kabbinavar F, et al. Safety of low-dose aspirin in a pooled analysis of 3 randomized, controlled trials of bevacizumab with chemotherapy in patients with metastatic colorectal cancer. J Clin Oncol. 2005;23(suppl):259s;(abstr 3554)
  24. Hambleton J, Novotny W, Hurwitz H, et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol. 2004;22:252;(abstr 3528)
  25. Ko J, Ross J, Awad H, et al. The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice. J Surg Res. 2005;129:251–259
  26. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91:173–180
  27. Berry S, Michael M, Kretzschmar A, et al. Starting bevacizumab shortly after venous access device implantation appears not to increase wound healing/bleeding complications nor catheter-related thromboses: Preliminary results from First BEAT. 2006;Presented at the 2006 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, San Francisco, CA, January 28-30, (abstr 245)
  28. Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol. 2006;23:4853–4855
  29. Sugrue M, Kozloff M, Hainsworth J, et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol. 2006;24(suppl):154s;(abstr 3535)
  30. Kozloff M, Hainsworth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). J Clin Oncol. 2006;24(suppl):155s;(abstr 3537)
  31. Hedrick EE, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). J Clin Oncol. 2006;24(suppl):155s;(abstr 3536)
  32. Kretzschmar A Cunningham D, Berry S, et al. Incidence of gastrointestinal perforations and bleeding in patients starting bevacizumab treatment in first-line mCRC without prior tumour resection: Preliminary results from the First BEAT trial. 2006;Poster presented at the 2006 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, San Francisco, CA, January 28-30, (abstr 248)
  33. Van Cutsem E, Michael M, Berry S, et al. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI, and capecitabine for mCRC: First BEAT trial. 2006;Presented at the 2006 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, San Francisco, CA, January 28–30, (abstr 250)
  34. Fyfe GA, Hurwitz H, Fehrenbacher L, et al. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. J Clin Oncol. 2004;24:274;(abstr 3617)

PII: S0093-7754(06)00312-5

doi: 10.1053/j.seminoncol.2006.08.001

Seminars in Oncology
Volume 33 , Pages S26-S34 , October 2006

Article Tools